Clinical Trials · NCT06221969
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,024
- Start date
- Jan 2024
- Locations
- 196 sites, 8 countries
- Primary endpoint
- Change in glycated haemoglobin (HbA1c)